Summary.-Serial serum diphenylhydantoin and urinary 5-(p-hydroxyphenyl)-5-phenylhydantoin concentrations were determined in 8 patients with malignant disease and 4 healthy volunteers on 2 separate occasions after an oral dose of diphenylhydantoin (500 mg). No significant difference was observed between metabolism before and 10 days after immunization with BCG or Corynebacterium parvum. Volunteers without intervening immunization similarly showed no difference.
IMMUNOTHERAPY is being increasingly used in the treatment of patients with malignant neoplasia. Two commonly used immunotherapeutic agents, Bacillus Calmette-Guerin (BCG) and Corynebacterium parvum (C. parvum) have, however, been shown to suppress the hepatic metabolism of drugs in animals (Farqhuar et al., 1975; Soyka et al., 1976) . As chemotherapy may be administered concurrently with immunotherapy, and as some cytotoxic drugs depend on hepatic enzymes for activation or detoxification, we elected to study the influence of BOG and C. parvum on hepatic drug hydroxylation in man.
MATERIALS AND METHODS
Subjects.-8 patients with disseminated malignancy were studied, after informed consent had been obtained. No patient had received previous radiotherapy or chemoimmunotherapy; other clinical details are shown in Table I . Liver function, as judged by routine biochemical and radiolabelled isotopic screening, was normal. Four healthy volunteers were also included in the study.
Immunization.-BCG vaccine (percutaneous Glaxo) was reconstituted with 0 3 ml sterile water (average number of organisms 1-5 x 108) and administered by "multiple puncture gun". Five applications of vaccine (100 needle punctures 2 mm depth) were given in each limb.
C. parvum (Burroughs-Wellcome CN6 134) 2 mg/M2 was given in 300 ml of saline over 3 h by i.v. infusion.
Study
protocol. -Diphenylhydantoin (Phenytoin, Parke-Davis) 500 mg orally was given at 1100 p.m. on Day 1 on an empty stomach. Blood samples were collected at 10, 14, 18, 22, 34, 38, 42, 46 toin and 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HHH) were determined by highpressure liquid chromatography using a modification of the procedure described by Kabra & Marton (1976) .
An aliquot of each urine sample (0.25 ml) was acidified with 12N HCI (0-25 ml), heated in a steam bath for 1 h, the resulting hydrolysate cooled, and the pH adjusted to 6-3 by the addition of an alkaline buffer (IM NaHCO3; 7-5M NaOH). Ethyl acetate/ dichloromethane (10 ml) (1:2, v:v) was then added and the tube agitated for 5 min. After centrifugation, the aqueous layer was decanted and the organic phase washed twice with 3 ml 0-6M NaHCO3. The aqueous phase was again removed, the organic phase evaporated to dryness in a rotary evaporator and the residue reconstituted with methanol (250 jul) before assay.
Separation and quantiation of phenytoin and p-HPPH was achieved with the use of a Perkin-Elmer LC 55 liquid chromatograph equipped with a spheresorb S 5W reversephase column (10 x 0 46 cm). The developing system used was water-methanol (75: 25, v: v) with a flow rate of 2 ml/min at 1000 lb/in2. Absorption was monitored at 254 nm and peak areas determined using an integrator (Infrotonics CRS 309). Samples of urine extract (5 ,ul) were applied directly to the column. Concentrations were determined by reference to calibration curves constructed from authentic standards, added to urine and extracted as described. In all instance, the relationship between absorbance (in arbitrary units) and drug concentrations were linear. All samples were determined in duplicate.
Kinetic analysis.-The areas under each concentration/time curve (AUC in mg.h/l) from 10 to 58 h were determined by the Trapezoidal method. The values for Km (mg/I) and Vmax (mg/l/day) derived from these individual curves were estimated using Michaelis-Mentin kinetics and an iterative computer programme.
Statistics.-Paired Student's t tests were used to determine the within-patient variation in the derived experimental values.
RESULTS
The mean age, sex, body weight and diagnosis of the 8 patients are given in Table I . Six patients had metastatic melanoma, 1 had metastatic rectal car- (Table II) .
The proportion of the administered dose excreted in the urine as p-HPPH during the first 72 h after administration is given in Table III . No difference was found between the 2 tests in healthy volunteers or patients. It was noted that the subjects who excreted the major proportion of the dose on the first day of the study did so when the test was repeated. No difference was seen between the healthy controls and the patients.
DISCUSSION
Diphenylhydantoin was selected as the test drug because the plasma half-time correlates well with other drugs of therapeutic relevance, for example, amylobarbitone, glutethimide and sulphinpyrazone (Brien et al., 1975) . It was considered that phenytoin was the most suitable drug for study in this context. Though there is suggestive evidence that chronic administration of phenytoin in epileptic patients may cause immunosuppression (Sorrell et al., 1971; Sorrell & Forbes, 1975) , it was considered extremely unlikely that a single 500mg dose would produce immunosuppression, and there is as yet no described relationship between immunosuppression and impaired hepatic metabolism. Similarly, whilst chronic administration of phenytoin may produce enzyme induction (Petruch et al., 1974) there was no evidence of this in the control patients.
The decay of serum phenytoin in man is not a simple first-order process (Arnold & Gerber, 1970) . The dose-dependent decay is explained by saturation of the drugmetabolizing system, and appears to change from zero to first order as the serum concentration decreases (Bochner et at., 1972) . Elimination can be explained by Michaelis-Mentin kinetics (Arnold & Gerber, 1970; Gerber & Wagner, 1972 ) and a computer programme is available which fits the serum concentration/time curve after an oral loading dose of phenytoin (Mawer et al., 1974 The values so derived indicate that immunotherapy using either BCG or C. parvum had no statistically significant effect on the metabolism of phenytoin in the patients studied. Similarly, no difference was seen in the proportion of urinary p-HPPH excreted during the first 48 h, in both patients and healthy volunteers. One interesting observation was the significantly smaller values for AUC in the patients than in the healthy volunteers. This observation suggests that liver metabolism may be altered in patients with no clinical or biochemical evidence of metastatic hepatic infiltration, an observation that may have therapeutic relevance.
Thus, immunotherapy alone does not impair the ability of the Jiver to hydroxylate phenytoin and presumably, therefore, the ability to metabolize other drugs that are handled similarly. It is not possible to predict from this study whether metabolism would be impaired by repeated administration of either BCG or C. parvum. A different sampling schedule may have detected a change, but the 10-day interval was selected on projection from animal data (Farquhar et al., 1975; Mosedale & Smith, 1975) and because peak immunostimulation occurs 10-14 days after immunotherapy (Thatcher et al., 1978) . There is, however, evidence that the concurrent administration of immunotherapeutic stimulants and cyclophosphamide will depress aminopyrene N-demethylation (Lipton et al., 1977) and therefore, caution should be exercised when combining these 2 treatment modalities.
